Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Brief Summary: This is a multicenter, open label, Phase 1/2 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 (larotrectinib) will be administered orally (PO) twice daily (BID), with the dose adjusted by body surface area (BSA).